News | November 18, 2011

New Analysis of Data Presented at AHA: Prasugrel’s Effect on Cardiovascular Events in STEMI Patients According to Timing of PCI


November 18, 2011 – An analysis of the TRITON-TIMI 38 trial presented today in an oral session at the American Heart Association (AHA) Scientific Sessions meeting examined the effect of Effient (prasugrel) on cardiovascular (CV) events (CV death, myocardial infarction [MI] and stroke) compared to clopidogrel relative to the timing of percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) patients with ST-segment elevation myocardial infarction (STEMI).

At 15 months, primary PCI patients with STEMI had an 11 percent relative risk reduction in CV events, and secondary PCI patients had a 35 percent relative risk reduction with Effient compared to clopidogrel (HR 0.89, 95% CI 0.69-1.13; and HR 0.65, 95% CI 0.46-0.93, respectively). Absolute risk reduction for Effient compared to clopidogrel was 1.3 percent for the primary PCI group and 4.6 percent for the secondary PCI group. (1)

"Not all ST-elevation MI patients are treated with primary PCI; therefore, understanding the effects of more potent inhibition of platelets in ACS patients who are treated with primary PCI or those treated with delayed PCI is important for choosing antiplatelet therapies," said lead author Jacob A. Udell, M.D., MPH, clinical fellow, cardiovascular medicine, Brigham & Women's Hospital. "These data demonstrate that efficacy and bleeding rates for Effient are consistent with the overall TRITON-TIMI 38 trial results irrespective of when STEMI patients undergo intended PCI."

In the study, primary PCI was defined as PCI within 12 hours from onset of acute coronary syndrome (ACS) symptoms and secondary PCI was defined as PCI more than 12 hours after initial onset or initial medical therapy. Of the 3,534 STEMI patients from the TRITON-TIMI 38 trial who were included in this analysis, 2,340 (68 percent) underwent primary PCI and 1,085 underwent secondary PCI. Randomization to Effient or clopidogrel occurred at presentation if primary PCI was intended or at the time of secondary PCI. The primary endpoint of the analysis was a reduction in the composite of CV death, MI and stroke.

In this analysis, TIMI major non-CABG bleeding events at 15 months occurred in 3 percent of prasugrel-treated primary PCI patients and 1.9 percent of clopidogrel-treated patients (HR=1.52, p=0.13); TIMI non-CABG major or minor bleeding occurred in this patient group in 5 percent of clopidogrel-treated patients and 6 percent of prasugrel-treated patients (HR=1.33, p=0.12). In secondary PCI patients, TIMI major non-CABG bleeding events occurred in 2.5 percent of clopidogrel-treated patients and 0.9 percent of prasugrel-treated patients (HR=0.39, p=0.07); TIMI non-CABG major or minor bleeding events occurred in 5 percent of clopidogrel-treated patients compared to 3 percent of prasugrel-treated patients (HR=0.57, p=0.09).(1) TIMI major non-CABG bleeding events associated with prasugrel as compared to clopidogrel were consistent in the STEMI cohort compared to the overall trial. Within the PCI subgroup, the hazard of bleeding with primary PCI at 15 months was HR 1.52 [CI 0.87-2.65] and for secondary PCI at 15 months was HR 0.39 [CI 0.14-1.11].(1)

Overall TRITON-TIMI 38 Study Methodology

TRITON-TIMI 38 was a head-to-head study comparing Effient (60-mg loading dose [LD], followed by a 10-mg once-daily maintenance dose) plus aspirin (ASA) with Plavix (clopidogrel) (300-mg LD, followed by a 75-mg once-daily maintenance dose) plus ASA in 13,608 patients with ACS managed with percutaneous coronary intervention (PCI), a procedure to open blockages in heart arteries, including the use of coronary stenting. The median duration of study treatment was 14.5 months.(2)

The primary endpoint of the study was the combined incidence of cardiovascular death, non-fatal heart attack or non-fatal stroke in patients followed for six to 15 months following PCI. The study showed that treatment with Effient produced a statistically significant 18 percent reduction in the relative risk of the combined measure of cardiovascular death, nonfatal heart attack or nonfatal stroke compared with Plavix in people with chest pain at rest or milder heart attacks (unstable angina/ non-ST segment myocardial infarction) (9.3 vs. 11.2 percent respectively, p=0.002) and a 21 percent significant reduction in the combined endpoint in people with more severe heart attacks (ST elevation myocardial infarction) (9.8 vs. 12.2 percent respectively, p=0.019).(3) This corresponds to a 1.9 percent absolute risk reduction for UA/NSTEMI patients treated with Effient and a 2.4 percent absolute risk reduction for STEMI patients treated with Effient.(2) TRITON-TIMI 38 patients treated with Effient also experienced a 50 percent relative risk reduction (corresponding to 1.3 percent absolute risk reduction) in stent-related clots when compared with Plavix, regardless of stent type (1.1 percent vs. 2.4 percent respectively, p<0.001).(2) In TRITON, the risk of non-coronary artery bypass graft (non-CABG) major bleeding, including fatal bleeding, was higher with Effient (2.2 percent incidence) compared with Plavix (1.7 percent incidence) (p=0.029).(2) The rate of TIMI major or minor bleeding was significantly greater with Effient than Plavix (5.0 percent vs. 3.8 percent respectively, p=0.002). The risk of coronary artery bypass graft (CABG) major bleeding, including fatal bleeding, was higher with Effient (13.4 percent incidence) than Plavix (3.2 percent incidence) (p<0.001).(2) In TRITON-TIMI 38, the LD of Plavix was delayed relative to the placebo-controlled trials that supported its approval for ACS.

Compared with the overall study population, a higher risk of serious bleeding among Effient patients was most evident in three distinct patient populations that are readily identifiable: patients who weighed less than 132 pounds (60 kg), patients who were 75 years of age or older and patients who have had a prior transient ischemic attack (TIA) or stroke.(3) A 5 mg maintenance dose may be considered for patients who weigh less than 132 lbs.(3) Effient is generally not recommended for use in patients 75 years or older,(3) except in high risk patients (diabetes or prior MI), where its effects appears to be greater and its use may be considered.(3) Patients with prior TIA or stroke should not be treated with Effient.(3)

For more information:


 (1) Udell JA et al. Benefit of Prasugrel in ST-elevation Myocardial Infarction According to Timing of Percutaneous Coronary Intervention: Insights from the TRITON-TIMI 38 Study. To be presented at the American Heart Association Scientific Sessions; November 2011; Orlando FL.

(2) Wiviott, S.D. et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine 2007 Vol 357 (20); 2001-2015.

(3) Effient (prasugrel) prescribing information. Daiichi Sankyo, Inc. and Eli Lilly and Company.

(4) Roger VL, Go AS, Lloyd-Jones DM, et al. for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2011 update. Circulation. 2011;123:e1-e192.

(5) Kolansky DM. Acute coronary syndromes: Morbidity, mortality, and pharmacoeconomic burden. Amer. J. of Managed Care. 2009;15:S36-S41.


Related Content

COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease
Feature | Antiplatelet and Anticoagulation Therapies| September 12, 2017
September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies| August 28, 2017
August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc.
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Study Discovers Anticoagulant Drugs Are Being Prescribed Against Safety Advice
News | Antiplatelet and Anticoagulation Therapies| July 25, 2017
July 25, 2017 — A study by researchers at the University of Birmingham has shown that general practitioners (GPs) are
Alere point of care POC testing for INR
News | Point of Care Testing| July 17, 2017 | Dave Fornell
July 17, 2017 — Despite issues with point-of-care INR testing company Alere Inc., Abbott announced this week it is on
long-duration dual anti-platelet therapy (L-DAPT) compared to short-duration dual antiplatelet (S-DAPT) after DES stent implantation
News | Antiplatelet and Anticoagulation Therapies| July 12, 2017
June 12, 2017 — Researchers have evaluated the long-term efficacy and safety of long-duration dual anti-platelet ther
FDA Grants Priority Review of Xarelto sNDA for 10 mg Dose
News | Antiplatelet and Anticoagulation Therapies| June 29, 2017
Janssen Research & Development LLC announced the U.S. Food and Drug Administration (FDA) accepted for Priority...
Overlay Init